Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Translational Stroke Research

• Publication date

  2017-03-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12975-017-0527-5PMID 28265861
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urinary kallidinogenase for the treatment of cerebral arterial stenosis

  2015cited by this paper
• Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association.

  2014cited by this paper
• Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

  2014cited by this paper
• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

  2013cited by this paper
• Barriers to the utilization of thrombolysis for acute ischaemic stroke

  2012cited by this paper
• Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: A systematic review

  2012cited by this paper
• Predicting outcome of IV thrombolysis–treated ischemic stroke patients

  2012cited by this paper
• Predicting outcome of IV thrombolysis-treated ischemic stroke patients: The DRAGON score

  2012cited by this paper
• Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR)

  2011cited by this paper
• A multicenter,randomized,double-blinded and placebo-controlled study of acute brain infarction treated by human urinary kallidinogenase

  2007cited by this paper
• Measurements of acute cerebral infarction: a clinical examination scale.

  1989cited by this paper
• Assessment of coma and impaired consciousness. A practical scale.

  1974cited by this paper
• Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis

  1957cited by this paper

• Adjunctive Human Urinary Kallidinogenase Enhances the Cognitive and Hemodynamic Outcomes of Anterior Circulation Stenting

  2025cites this paper
• Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke

  2023cites this paper
• Clinical Ageing.

  2023cites this paper
• Neuroprotective agents in acute ischemic stroke

  2023cites this paper
• Genetic plasma biomarkers associated with ischemic stroke

  2023cites this paper
• Human urinary kallidinogenase in acute ischemic stroke: A single‐arm, multicenter, phase IV study (RESK study)

  2021cites this paper
• Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

  2020cites this paper
• Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors

  2019cites this paper
• Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism

  2019cites this paper
• Human tissue kallikrein in the treatment of acute ischemic stroke

  2019cites this paper
• Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.

  2018cites this paper
• The Combination of Human Urinary Kallidinogenase and Mild Hypothermia Protects Adult Rats Against Hypoxic-Ischemic Encephalopathy-Induced Injury by Promoting Angiogenesis and Regeneration

  2018cites this paper
• Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases

  2018cites this paper